Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Trial Parameters
Brief Summary
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 years or older who provided written informed consent 2. Patients who schedule to undergo bariatric surgery and a liver biopsy (LB) for the investigation of suspected MASLD 3. Patients who schedule to undergo FibroScan examination Exclusion Criteria: 1. Patients with ascites or pregnant women 2. Patients with any active implantable medical device (such as a pacemaker or defibrillator) 3. Patients who have undergone liver transplantation 4. Patients with cardiac failure and/or significant valvular disease 5. Patients with haemochromatosis 6. Patients who have refused to undergo LB or blood tests 7. Patients with a confirmed diagnosis of active malignancy, or other terminal disease 8. Patients participating in another clinical trial within the preceding 30 days